Overview
Rare cancers suffer from limited data and small cohorts which impede evidence generation; imaging registries aggregate standardized imaging, clinical and outcome data to enable research and real world evidence. Registries support natural history studies, biomarker discovery and trial readiness. Multicenter collaboration and harmonized protocols are essential for registry value.
Data Standards and Curation
Adopt standardized imaging protocols, DICOM metadata conventions and structured reporting templates to ensure data comparability across sites. Curate datasets with quality checks, de identification and provenance tracking to support reproducible research. Link imaging to clinical registries and biospecimen repositories for multimodal analyses.
Governance and Access
Establish transparent governance for data access, authorship and benefit sharing and include patient representatives in oversight. Implement secure data sharing platforms and tiered access to balance research utility with privacy protection. Provide clear processes for external researchers to request and use registry data.
Impact and Use Cases
Registries enable pooled analyses to identify imaging biomarkers, support regulatory submissions and inform clinical guidelines for rare cancers. They facilitate trial recruitment by identifying eligible patients and provide real world safety and effectiveness data post approval. Sustained funding and stakeholder engagement are critical for long term registry success.